Sector News

Actavis cuts 200 California jobs, providing a glimpse of what is in store at Allergan

December 3, 2014
Life sciences
California’s Allergan desperately wanted to avoid a hostile takeover by Valeant, fearful it would ravage its R&D operations in favor of its marketing oriented approach to the business. So it turned to Actavis as a white knight. But Actavis is also known to cut jobs with impunity to make deals pay and Allergan need look only a few miles down the road for proof of that as Actavis prepares to lay off 200 at it operations in Corona, CA.
 
The cuts, outlined in a state filing are set for Jan. 2, according to the Orange County Business Journal. Nothing more is outlined in terms of what kinds of jobs will be lost.
 
Actavis and Allergan just last month reached a quickly negotiated $66 billion deal, derailing months of effort by Valeant to buy the Botox maker for about $54 billion. One of Allergan’s arguments against pairing up with Valeant is a belief that it would take an ax to its R&D operations, cutting people to cut dollars. But in announcing its Allergan deal, Actavis noted that it can realize “at least $1.8 billion in annual synergies commencing in 2016, in addition to the $475 million of annual savings previously announced by Allergan.” And synergies inevitably mean job cuts.
 
In fact, Actavis has always been up front that duplication is part of any merger and so whacking jobs is an unpleasant necessity of growth. It has been just over a year ago that it announced it would lay off about 30% of its sales force in the U.S. after completing its its $8.5 billion merger with Warner Chilcott. That was about 350 jobs.
 
In July, after closing its deal to buy Forest Laboratories, it handed out pink slips to about 200 employees who had worked for Forest in the St. Louis, MO area. That came even as top execs were themselves handed up to $186 million in “merger success awards” for closing the $25 billion deal. Actavis has yet to say how many jobs might be lost as a result of its melding with Allergan but the Botox maker will be adding 11,500 employees to the approximately 25,000 Actavis already has.
 
As for the cuts in Corona, the Business Journal points out that it was the original home of the company that started out as Watson Pharmaceuticals, the small generics maker that has bought and built its way into an operation now slated to have $23 billion in annual revenue.
 
By Eric Palmer
 

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach